Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

Brian Tomlinson; Miao Hu; Yuzhen Zhang; Paul Chan; Zhong Min Liu

doi:10.1080/17425255.2016.1234608

Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	1267-1271
Number of pages	5
Journal	Expert Opinion on Drug Metabolism and Toxicology
Volume	12
Issue number	11
DOIs	https://doi.org/10.1080/17425255.2016.1234608
Publication status	Published - Nov 1 2016

Keywords

Alogliptin
dipeptidyl peptidase-4 inhibitors
empagliflozin
glucagon-like peptide-1 agonists
liraglutide
lixisenatide
saxagliptin
sitagliptin
sodium-glucose cotransporter 2 inhibitors
type 2 diabetes mellitus

ASJC Scopus subject areas

Toxicology
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/17425255.2016.1234608

Cite this

@article{dc682884230844c1b502b7b1041d90ce,

title = "Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes",

keywords = "Alogliptin, dipeptidyl peptidase-4 inhibitors, empagliflozin, glucagon-like peptide-1 agonists, liraglutide, lixisenatide, saxagliptin, sitagliptin, sodium-glucose cotransporter 2 inhibitors, type 2 diabetes mellitus",

author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",

year = "2016",

month = nov,

day = "1",

doi = "10.1080/17425255.2016.1234608",

language = "English",

volume = "12",

pages = "1267--1271",

journal = "Expert Opinion on Drug Metabolism and Toxicology",

issn = "1742-5255",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

AU - Tomlinson, Brian

AU - Hu, Miao

AU - Zhang, Yuzhen

AU - Chan, Paul

AU - Liu, Zhong Min

PY - 2016/11/1

Y1 - 2016/11/1

KW - Alogliptin

KW - dipeptidyl peptidase-4 inhibitors

KW - empagliflozin

KW - glucagon-like peptide-1 agonists

KW - liraglutide

KW - lixisenatide

KW - saxagliptin

KW - sitagliptin

KW - sodium-glucose cotransporter 2 inhibitors

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84988409411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988409411&partnerID=8YFLogxK

U2 - 10.1080/17425255.2016.1234608

DO - 10.1080/17425255.2016.1234608

M3 - Editorial

AN - SCOPUS:84988409411

SN - 1742-5255

VL - 12

SP - 1267

EP - 1271

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

IS - 11

ER -

Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this